Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Thymic Carcinoma
Explore 13 assets in Thymic Carcinoma →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
other_biological
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thymic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit (this asset) | Roswell Park Cancer Institute | P2 | B · 56 |
| Cyclophosphamide | Beijing Biotech | P2 | B |
| Fludarabine | Beijing Biotech | P2 | B |
| Cyclosporin A | Roswell Park Cancer Institute | P2 | B |
| Regorafenib | Istituto Clinico Humanitas | P2 | B |
| Melphalan | Roswell Park Cancer Institute | P2 | B |
| Selumetinib | National Cancer Institute (NCI) | P2 | B |
| Busulfanum | Roswell Park Cancer Institute | P2 | B |
| Lapatinib | National Cancer Institute (NCI) | P2 | CCC |
+18 more in the Thymic Carcinoma cohort
Other indications for Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 75 |
| Plasma Cell Myeloma | — | P4 | BBB · 72 |
| Myeloproliferative Neoplasm | — | P2/3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Human T-Lymphocyte Immunoglobulin, Rabbit in Thymic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-human-t-lymphocyte-immunoglobulin-rabbit-thymic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →